SG11201704980XA - Method of treatment - Google Patents
Method of treatmentInfo
- Publication number
- SG11201704980XA SG11201704980XA SG11201704980XA SG11201704980XA SG11201704980XA SG 11201704980X A SG11201704980X A SG 11201704980XA SG 11201704980X A SG11201704980X A SG 11201704980XA SG 11201704980X A SG11201704980X A SG 11201704980XA SG 11201704980X A SG11201704980X A SG 11201704980XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014905194A AU2014905194A0 (en) | 2014-12-22 | Method of Treatment | |
PCT/AU2015/050820 WO2016101024A1 (en) | 2014-12-22 | 2015-12-21 | Method of treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704980XA true SG11201704980XA (en) | 2017-07-28 |
Family
ID=56148784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704980XA SG11201704980XA (en) | 2014-12-22 | 2015-12-21 | Method of treatment |
Country Status (13)
Country | Link |
---|---|
US (2) | US10493067B2 (en) |
EP (1) | EP3236963B1 (en) |
JP (2) | JP2018500365A (en) |
KR (1) | KR20170098897A (en) |
CN (1) | CN107530337B (en) |
AU (1) | AU2015372434B2 (en) |
BR (1) | BR112017013015A2 (en) |
CA (1) | CA2971071A1 (en) |
EA (1) | EA201791455A1 (en) |
IL (1) | IL253028B (en) |
MX (1) | MX2017008248A (en) |
SG (1) | SG11201704980XA (en) |
WO (1) | WO2016101024A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017013015A2 (en) * | 2014-12-22 | 2018-03-06 | Cardiora Pty Ltd | method of treating a patient who has heart failure with preserved ejection fraction (hfpef) |
US11730733B2 (en) | 2020-12-10 | 2023-08-22 | Imbria Pharmaceuticals, Inc. | Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine |
US11793807B2 (en) | 2020-12-10 | 2023-10-24 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine |
US11969422B2 (en) | 2020-12-10 | 2024-04-30 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine |
WO2022125370A1 (en) * | 2020-12-10 | 2022-06-16 | Imbria Pharmaceuticals, Inc. | Methods of treating heart conditions using modified forms of trimetazidine |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4297360A (en) | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
US4313951A (en) | 1979-11-26 | 1982-02-02 | Sterling Drug Inc. | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor |
NZ195564A (en) | 1979-11-26 | 1983-09-30 | Sterling Drug Inc | 5-pyridinyl-2(1h)-pyridinones pharmaceutical compositions intermediate pyridine compounds |
GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
US5213811A (en) | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
SK279684B6 (en) | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tablet and process for its preparation |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
GB9402203D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
JP2005537298A (en) | 2002-08-02 | 2005-12-08 | ペンウェスト ファーマシューティカルズ カンパニー | Metformin sustained release formulation |
KR100548925B1 (en) | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | Sustained release composition for oral administration of a drug |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
ES2405404T3 (en) | 2003-10-29 | 2013-05-31 | Wyeth Llc | Pharmaceutical sustained release compositions comprising aplindore and its derivatives |
FR2891459B1 (en) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME |
CA2816448A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
WO2013002350A1 (en) * | 2011-06-29 | 2013-01-03 | 京都府公立大学法人 | Tumor site identification device and method |
CA2845228C (en) * | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
EP3112363A1 (en) | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension |
WO2013116194A2 (en) * | 2012-01-30 | 2013-08-08 | O'connell Timothy D | Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis |
BR112017013015A2 (en) * | 2014-12-22 | 2018-03-06 | Cardiora Pty Ltd | method of treating a patient who has heart failure with preserved ejection fraction (hfpef) |
-
2015
- 2015-12-21 BR BR112017013015A patent/BR112017013015A2/en not_active Application Discontinuation
- 2015-12-21 US US15/538,123 patent/US10493067B2/en active Active
- 2015-12-21 CA CA2971071A patent/CA2971071A1/en active Pending
- 2015-12-21 MX MX2017008248A patent/MX2017008248A/en unknown
- 2015-12-21 AU AU2015372434A patent/AU2015372434B2/en active Active
- 2015-12-21 SG SG11201704980XA patent/SG11201704980XA/en unknown
- 2015-12-21 KR KR1020177020214A patent/KR20170098897A/en unknown
- 2015-12-21 CN CN201580076215.4A patent/CN107530337B/en active Active
- 2015-12-21 EP EP15871347.9A patent/EP3236963B1/en active Active
- 2015-12-21 WO PCT/AU2015/050820 patent/WO2016101024A1/en active Application Filing
- 2015-12-21 JP JP2017534610A patent/JP2018500365A/en not_active Revoked
- 2015-12-21 EA EA201791455A patent/EA201791455A1/en unknown
-
2017
- 2017-06-20 IL IL253028A patent/IL253028B/en active IP Right Grant
-
2019
- 2019-12-02 US US16/700,237 patent/US11291660B2/en active Active
-
2021
- 2021-12-24 JP JP2021210184A patent/JP7475324B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
NZ732954A (en) | 2021-11-26 |
AU2015372434B2 (en) | 2018-10-04 |
US11291660B2 (en) | 2022-04-05 |
US10493067B2 (en) | 2019-12-03 |
JP2022163681A (en) | 2022-10-26 |
WO2016101024A1 (en) | 2016-06-30 |
EP3236963A1 (en) | 2017-11-01 |
EA201791455A1 (en) | 2017-12-29 |
US20170348292A1 (en) | 2017-12-07 |
EP3236963A4 (en) | 2018-08-08 |
CA2971071A1 (en) | 2016-06-30 |
AU2015372434A1 (en) | 2017-07-13 |
KR20170098897A (en) | 2017-08-30 |
JP2018500365A (en) | 2018-01-11 |
MX2017008248A (en) | 2018-02-19 |
EP3236963B1 (en) | 2020-01-29 |
JP7475324B2 (en) | 2024-04-26 |
BR112017013015A2 (en) | 2018-03-06 |
IL253028A0 (en) | 2017-08-31 |
IL253028B (en) | 2019-12-31 |
CN107530337A (en) | 2018-01-02 |
CN107530337B (en) | 2021-07-09 |
US20200101053A1 (en) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279627A (en) | Method for the treatment of depression | |
GB201701673D0 (en) | Methods of well treatment | |
HK1252568A1 (en) | A method of treatment | |
HK1248552A1 (en) | Method of treatment with tradipitant | |
SG11201607130RA (en) | Combination method for treatment of cancer | |
IL252296A0 (en) | Methods of treating multiple sclerosis | |
GB201410116D0 (en) | Method of treatment | |
GB201401430D0 (en) | Treatment process | |
GB2522719B (en) | Method of manufacture | |
SG10201912688YA (en) | A method of treatment | |
IL253028A0 (en) | Method of treatment | |
GB2525930B (en) | Method of authentication | |
GB201416832D0 (en) | Methods of treatment | |
HK1249866A1 (en) | Methods of treatment with taselisib | |
HK1244692A1 (en) | Methods of treating fibrosis | |
GB201602802D0 (en) | Method of treatment | |
HK1250243A1 (en) | A method of treatment | |
GB2522716B (en) | Method of manufacture | |
IL254336A0 (en) | Novel treatment method | |
GB201412010D0 (en) | Treatment of hypertransaminasemia | |
GB201512139D0 (en) | Methods of treatment | |
GB201421982D0 (en) | Method of treatment | |
GB201421980D0 (en) | Method of treatment | |
GB201415331D0 (en) | Method of treatment | |
GB201414780D0 (en) | Method Of Treatment |